Research index

ASX research

Durable archives for company coverage, sectors, and investment themes. Each hub links the dated editions that belong to it.

14 editions published since the archive reset.

Company archives

Sector archives

Theme archives

Latest research

  1. Zip's two-day rally prices a US turnaround before credit costs have finished their sayZip Co (ASX:ZIP) rallied again as payments risk came back into favour; the question is whether US cash profit can outrun credit costs.
  2. Liontown's lithium selloff puts Kathleen's ramp-up before the price cycleLiontown (ASX:LTR) fell with lithium names despite a stronger March quarter; the question is whether price beta is drowning out ramp-up evidence.
  3. Transurban's North America update puts toll growth against rate riskTransurban (ASX:TCL) fell 4.4% after a North America update. We test whether traffic-linked toll growth offsets debt, capex and project risk.
  4. Neuren's European Daybue jump puts one-drug royalties ahead of the pipelineNeuren (ASX:NEU) jumped after Daybue won an EU approval positive opinion; the question is how much royalty duration the tape just capitalised.
  5. a2 Milk's A$300m payout rides China-label registrations, not a birth-rate turna2 Milk (ASX:A2M) is paying out A$300m on the back of China-label registrations, not a birth-rate turn — can share gains outrun a shrinking market?
  6. Northern Star tracks bullion higher but the market still won't pay for record gold marginsNorthern Star (ASX:NST) is riding record gold prices, yet the market still won't pay for the margins. We test whether KCGM and Hemi can convert bullion into cash.
  7. Worley's A$110m FY26 hit is timing and currency; the tape priced a structural resetWorley (ASX:WOR) took an A$110m hit from timing and currency, but the tape priced a structural reset — do delayed Middle East awards convert to backlog?
  8. Judo's credit reset turns a growth-bank story into a cost-of-risk argumentJudo Bank's credit downgrade erased about 40% of ASX:JDO. We test whether three bad loans are idiosyncratic or a structural cost-of-risk reset.
  9. Pro Medicus's contract wins are real; its 160-times multiple is the wagerPro Medicus (ASX:PME) keeps winning marquee US imaging contracts, but a ~160x multiple is the real wager. We test whether 20%+ growth can outrun the valuation.
  10. Santos shed its takeover premium just as Barossa and Pikka come onlineSantos (ASX:STO) shed its takeover premium just as Barossa and Pikka come online. We test whether the ~30% production step-up converts to free cash as oil cools.
  11. Woodside has surrendered most of its oil-war spike, leaving the LNG build to set the priceWoodside (ASX:WDS) has given back most of its oil-war price spike, leaving the Scarborough LNG build to set the story — does the growth bill convert to cash?
  12. China's export blacklist re-rated Lynas from price-taker to strategic assetChina's rare-earth export blacklist re-rated Lynas (ASX:LYC) from price-taker to strategic asset. We test whether the NdPr premium and ex-China supply case hold.